Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

复方氨酚烷胺胶囊 - NMPA Drug Approval Details

Approvals/NMPA/Compound Paracetamol and Amantadine Hydrochloride Capsules

Approved

化学药品

Compound Paracetamol and Amantadine Hydrochloride Capsules

新宇药业股份有限公司🇨🇳 National Medical Products Administration

Approval Date: Mar 2, 2015
Approval ID: 7zxdbxjaxDQ
Company: 新宇药业股份有限公司
Type: 化学药品

Approval Details

Approval Id: 7zxdbxjaxDQ
Approval Number: 国药准字H34022065
Generic Name: 复方氨酚烷胺胶囊
Generic Name En: Compound Paracetamol and Amantadine Hydrochloride Capsules
Drug Type: 化学药品
Strength: 0.377g
Reg Date: 2015-03-02
Company Name: 新宇药业股份有限公司
Production Company Address: 安徽省宿州市淮海路24号
Company Detail Path: /organization/xin-yu-yao-ye-gu-fen-you-xian-gong-si

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Mar 2, 2015

Approval ID

7zxdbxjaxDQ

Type

化学药品

Back to NMPA Approvals